This publication was commissioned by Roche Products (New Zealand) Ltd following a Roche organised and funded educational event held on Wednesday 1st May 2024 covering the use of faricimab (Vabysmo®) for the treatment of neovascular age-related macular degeneration and diabetic macular oedema. Faricimab received Medsafe registration for these indications in October 2023. The publication was reviewed and edited by Roche to ensure accuracy and compliance with the Medicines New Zealand Code of Practice. Treatment decisions based on these data are the full responsibility of the prescribing physician; consult the Data Sheet at www.medsafe.govt.nz before prescribing.
The event was chaired by Dr Ainsley Morris from EyeAM, Christchurch, who also gave the opening presentation, and featured presentations by Professor Robyn Guymer from the Centre for Eye Research Australia, and Dr David Worsley from the Hamilton Eye Clinic, Hamilton. Case studies were presented by Dr Ainsley Morris, Dr Sean Every from Southern Eye Specialists, Christchurch and Dr Joel Yap from Auckland Eye, Auckland.
Please login below to download this issue (PDF)